| Literature DB >> 31771186 |
Fang-Pin Chang1, Shyh-Shyun Huang2, Tzong-Huei Lee3, Chi-I Chang4, Tzong-Fu Kuo5, Guan-Jhong Huang6, Yueh-Hsiung Kuo1,6,7,8.
Abstract
One new iridoid, namely neonanin C (1) one monocyclic iridoid ring-opened derivative namely neonanin D (2), two new bis-iridoid derivatives namely reticunin A (3) and reticunin B (4) with sixteen known compounds (5-20) were isolated from the stems of Neonauclea reticulata (Havil.) Merr. These new structures were determined by the detailed analysis of spectroscopic data and comparison with the data of known analogues. Compounds 1-20 were evaluated for inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages cell line. The results showed that all compounds exhibited no obvious cytotoxicity compared to the control group and five compounds including isoboonein (7), syringaresinol (10), (+)-medioresinol (12), protocatechuic acid (14) and trans-caffeic acid (15) exhibited inhibitory activities with IC50 values at 86.27 ± 3.45; 9.18 ± 1.90; 76.18 ± 2.42; 72.91 ± 4.97 and 95.16 ± 1.20 µg/mL, respectively.Entities:
Keywords: Neonauclea reticulata; RAW264.7; bis-iridoid; iridoid; neonanin; reticunin
Mesh:
Substances:
Year: 2019 PMID: 31771186 PMCID: PMC6930649 DOI: 10.3390/molecules24234271
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The chemical structures of compound 1–20 from Neonauclea reticulata (Havil.) Merr.
1H-NMR and 13C-NMR spectroscopic data of compounds 1–2 (in CDCl3, 500 MHz) a.
| Compounds | 1 | 2 | ||
|---|---|---|---|---|
| Position | 1H a | 13C | 1H a | 13C |
| 1 | 173.7 | 4.21 (dd, | 65.4 | |
| 4.44 (dd, | ||||
| 2 | ||||
| 3 | 5.90 (brs) | 94.7 | 3.77 (dd, | 63.6 |
| 3.89 (dd, | ||||
| 4 | 2.59 (dd, | 50.0 | 2.70 (ddd, | 48.3 |
| 5 | 3.32 (m) | 32.0 | 2.99 (m) | 37.0 |
| 6α | 1.45 (td, | 42.0 | 1.65 (td, | 39.1 |
| 6β | 2.33 (m) | 1.95 (dd, | ||
| 7 | 4.14 (q, | 75.0 | 4.24 (q, | 75.1 |
| 8 | 2.30 (m) | 43.6 | 2.05 (m) | 42.4 |
| 9 | 2.88 (t, | 46.2 | 2.22 (m) | 44.9 |
| 10 | 1.28 (d, | 14.4 | 1.13 (d, | 14.2 |
| 11 | 170.6 | 175.4 | ||
| 11-O | 3.78 (s) | 52.7 | 3.67 (s) | 52.2 |
| 1′ | 130.4 | |||
| 2′ | 8.00 (d, | 129.7 | ||
| 3′ | 7.45 (t, | 128.7 | ||
| 4′ | 7.57 (t, | 133.3 | ||
| 5′ | 7.45 (t, | 128.7 | ||
| 6′ | 8.00 (d, | 129.7 | ||
| 7′ | 166.8 | |||
a The chemical shifts are expressed in δ ppm. The coupling constants (J) are expressed in Hz.
Figure 2(a) Significant COSY (bold line) correlations and (HMBC) () correlations for compounds 1–4; (b). Significant NOESY () correlations of compounds 1–4.
Figure 3Proposed biosynthetic sequence of neonanin D (2).
1H-NMR and 13C-NMR spectroscopic data of compounds 3–4 (in CDCl3, 500 MHz) a.
| Compound | 3 | Compound | 4 | ||
|---|---|---|---|---|---|
| Position | 1H a | 13C | Position | 1Ha | 13C |
| 1 | 174.1 | 1 | 173.5 | ||
| 2 | 2 | ||||
| 3 | 5.63 (d, | 98.3 | 3 | 5.59 (d, | 98.1 |
| 4 | 2.60 (dd, | 50.1 | 4 | 2.59 (dd, | 50.0 |
| 5 | 3.31 (m) | 32.0 | 5 | 3.33 (m) | 32.1 |
| 6α | 1.42 (m) | 42.3 | 6α | 1.42 (m) | 42.3 |
| 6β | 2.34 (dd, | 6β | 2.35 (dd, | ||
| 7 | 4.12 (m) | 75.1 | 7 | 4.13 (m) | 75.1 |
| 8 | 2.27(m) | 43.7 | 8 | 2.29 (m) | 43.6 |
| 9 | 2.79 (dd, | 46.2 | 9 | 2.77 (dd, | 46.1 |
| 10 | 1.29 (d, | 14.6 | 10 | 1.29 (d, | 14.6 |
| 11 | 169.7 | 11 | 169.8 | ||
| 11-O | 3.82 (s) | 52.7 | 11-O | 3.77, s | 52.6 |
| 1′ | 4.93 (d, | 95.7 | 1′ | 173.3 | |
| 2′ | 2′ | ||||
| 3′ | 7.40 (d, | 151.5 | 3′α | 4.45 (dd, | 67.5 |
| 3′β | 4.25 (dd, | ||||
| 4′ | 111.8 | 4′ | 2.52 (td, | 46.1 | |
| 5′ | 2.93 (q, | 31.7 | 5′ | 2.84 (m) | 37.4 |
| 6′α | 1.37 (m) | 38.2 | 6′α | 1.37 (m) | 37.3 |
| 6′β | 2.42 (dd, | 6′β | 2.30 (m) | ||
| 7′ | 4.20 (m) | 80.4 | 7′ | 4.23 (m) | 81.0 |
| 8′ | 1.97 (m) | 40.9 | 8′ | 2.40 (m) | 43.9 |
| 9′ | 1.89 (td, | 46.8 | 9′ | 2.64 (dd, | 46.2 |
| 10′ | 1.08 (d, | 13.9 | 10′ | 1.19 (d, | 14.7 |
| 11′ | 167.6 | 11′ | 171.2 | ||
| 11′-O | 3.71 (s) | 51.4 | 11′-O | 3.74 (s) | 52.6 |
a The chemical shifts are expressed in δ ppm. The coupling constants (J) are expressed in Hz.
In vitro inhibition of nitric oxide production of compounds 1–20 on NO production by LPS stimulated in RAW264.7 cells.
| Compounds | CC50 (μg/mL) a | IC50 (μg/mL) a | Compounds | CC50 (μg/mL) a | IC50 (μg/mL) a |
|---|---|---|---|---|---|
|
| >100 b | >100 |
| >100 b | >100 |
|
| >100 b | >100 |
| >100 b | 76.18 ± 2.42 *** |
|
| >100 b | >100 |
| >100 b | >100 |
|
| >100 b | >100 |
| >100 b | 72.91 ± 4.97 ** |
|
| >100 b | >100 |
| >100 b | 95.16 ± 1.20 *** |
|
| >100 b | >100 |
| >100 b | >100 |
|
| >100 b | 86.27 ± 3.45 *** |
| >100 b | >100 |
|
| >100 b | >100 |
| >100 b | >100 |
|
| >100 b | >100 |
| >100 b | >100 |
|
| >100 b | 9.18 ± 1.90 *** |
| >100 b | >100 |
|
| >100 b | >100 | Indomethacin | >100 b | 46.71 ± 3.14 |
a The values shown are the mean ± SD of data from three independent experiments; b CC50 could not be obtained because of a cell survival rate > 88% at 100-6.25 μg/mL; ** p < 0.01, *** p < 0.001 vs Indomethacin.